Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND Many patients who require migraine preventive treatment have not been able to tolerate or have not responded to multiple previous preventive medications. We aimed to assess the safety and efficacy of galcanezumab, an antibody to calcitonin gene-related peptide, in patients with migraine who had not benefited from preventive medications from two to four categories. METHODS CONQUER was a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial done at 64 sites (hospitals, clinics, or research centres) in 12 countries (Belgium, Canada, Czech Republic, France, Germany, Hungary, Japan, the Netherlands, South Korea, Spain, the UK, and the USA). Patients were 18-75 years of age, with episodic or chronic migraine, with migraine onset before the age of 50 years, who had a documented failure of preventive medications from two to four drug categories in the past 10 years owing to lack of efficacy or tolerability, or both. Patients were randomised 1:1 to receive subcutaneous placebo or galcanezumab 120 mg per month (with a 240 mg loading dose administered as two 120 mg injections) for 3 months. For masking purposes, patients receiving placebo also received two injections during the first dosing visit. Randomisation was done by a computer-generated random sequence by means of an interactive web-response system stratified by country and migraine frequency (low frequency episodic migraine, four to fewer than eight migraine headache days per month; high frequency episodic migraine, eight to 14 migraine headache days per month and fewer than 15 headache days per month; chronic migraine, at least eight migraine headache days per month and at least 15 headache days per month). The primary endpoint was the overall mean change from baseline in number of monthly migraine headache days during the 3-month treatment period in all patients who were randomly assigned and received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT03559257, and is now completed. FINDINGS Between Sept 10, 2018, and March 21, 2019, 462 participants with episodic (269 [58%]) or chronic (193 [42%]) migraine were randomly assigned and received at least one injection with placebo (n=230) or galcanezumab (n=232). Galcanezumab-treated patients had significantly greater reduction in migraine headache days versus placebo across months 1-3. The galcanezumab group had on average 4·1 fewer monthly migraine headache days compared with baseline (13·4), while the placebo group had on average 1·0 fewer than at baseline (13·0; between-group difference -3·1 [95% CI -3·9 to -2·3]; p<0·0001; effect size=0·72). Types and number of treatment-emergent adverse events were similar between galcanezumab and placebo. Treatment-emergent adverse events were reported in 122 (53%) of 230 patients in the placebo group and 119 (51%) of 232 patients in the galcanezumab group. There were four serious adverse events during the study, two (1%) reported in the placebo group and two (1%) reported in the galcanezumab group. INTERPRETATION Galcanezumab was superior to placebo in the preventive treatment of migraine and was safe and well tolerated in patients for whom multiple previous standard-of-care preventive treatments had failed. Galcanezumab might represent an important treatment option for patients who have not benefited from or tolerated previous standard-of-care treatments. FUNDING Eli Lilly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
The International Classification of Headache Disorders, 3rd edition (beta version)
Headache Classification Committee of the International Headache Society (IHS) (2013) · Cephalalgia · doi:10.1177/0333102413485658 · Cited by 8,229
Stewart, W. F., Lipton, R. B., Dowson, A. J., & Sawyer, J. (2001) · Neurology · doi:10.1212/wnl.56.suppl_1.s20 · Cited by 1,210
Silberstein, S. D., Holland, S., Freitag, F., Dodick, D. W., Argoff, C., & Ashman, E. (2012) · Neurology · doi:10.1212/wnl.0b013e3182535d20 · Cited by 897
Blumenfeld, A., Varon, S., Wilcox, T., Buse, D., Kawata, A., Manack, A., Goadsby, P., & Lipton, R. (2011) · Cephalalgia · doi:10.1177/0333102410381145 · Cited by 627
Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study
Detke, H. C., Goadsby, P. J., Wang, S., Friedman, D. I., Selzler, K. J., & Aurora, S. K. (2018) · Neurology · doi:10.1212/wnl.0000000000006640 · Cited by 563
Self-citationStauffer, V. L., Dodick, D. W., Zhang, Q., Carter, J. N., Ailani, J., & Conley, R. R. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1212 · Cited by 559
Stewart, W., Lipton, R., Kolodner, K., Liberman, J., & Sawyer, J. (1999) · Cephalalgia · doi:10.1046/j.1468-2982.1999.019002107.x · Cited by 556
Cited by
Ferrari, M. D., Goadsby, P. J., Burstein, R., Kurth, T., Ayata, C., Charles, A., Ashina, M., van den Maagdenberg, A. M. J. M., & Dodick, D. W. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00328-4 · Cited by 500
Sacco, S., Amin, F. M., Ashina, M., Bendtsen, L., Deligianni, C. I., Gil-Gouveia, R., Katsarava, Z., MaassenVanDenBrink, A., Martelletti, P., Mitsikostas, D.-D., et al. (2022) · The Journal of Headache and Pain · doi:10.1186/s10194-022-01431-x · Cited by 410
Vandervorst, F., Van Deun, L., Van Dycke, A., Paemeleire, K., Reuter, U., Schoenen, J., & Versijpt, J. (2021) · The Journal of Headache and Pain · doi:10.1186/s10194-021-01335-2 · Cited by 121
Metadata
- Authors
- Mulleners, W. M., Kim, B.-K., Láinez, M. J. A., Lanteri-Minet, M., Pozo-Rosich, P., Wang, S., Tockhorn-Heidenreich, A., Aurora, S. K., Nichols, R. M., Yunes-Medina, L., & Detke, H. C.
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 19
- Issue
- 10
- Pages
- 814-825
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W3086189755
- Cited by
- 270
- References
- 30
- FWCI
- 24.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. https://app.cochat.ai/papers/10.1016/s1474-4422(20)30279-9
- The paper
- Mulleners, W. M., Kim, B.-K., Láinez, M. J. A., Lanteri-Minet, M., Pozo-Rosich, P., Wang, S., Tockhorn-Heidenreich, A., Aurora, S. K., Nichols, R. M., Yunes-Medina, L., & Detke, H. C. (2020). Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(20)30279-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.